Clara N Curiel

Clara N Curiel

Director, Cutaneous Oncology Program
Division Chief, Dermatology
Member of the Graduate Faculty
Professor, BIO5 Institute
Professor, Medicine - (Tenure Track)
Primary Department
Department Affiliations
(520) 626-0307

Research Interest

Clara Curiel-Lewandroski, PhD, is the director of the Pigmented Lesion Clinic and Multidisciplinary Cutaneous Oncology Program, both part of the University of Arizona Cancer Center Skin Cancer Institute. She completed two research fellowships, the first in the Department of Dermatology at Harvard Medical School, and the second at the Ludwig Boltzman Institute and Immunobiology of the Skin at Miinster University in Germany. Dr. Curiel is certified by the American Board of Dermatology.Dr. Curiel-Lewandroski’s research focus is on melanoma chemoprevention, early detection of melanoma, cutaneous T cell lymphomas and skin cancer. She studied the extended use of non-steroidal anti-inflammatory drugs, particularly aspirin, and their ability to possibly decrease the risk of cutaneous medanoma (CM) development. CM is responsible for more than 77 percent of skin cancer deaths.


Malvehy, J., Hauschild, A., Curiel-Lewandrowski, C., Mohr, P., Hofmann-Wellenhof, R., Motley, R., Berking, C., Grossman, D., Paoli, J., Loquai, C., Olah, J., Reinhold, U., Wenger, H., Dirschka, T., Davis, S., Henderson, C., Rabinovitz, H., Welzel, J., Schadendorf, D., & Birgersson, U. (2014). Clinical performance of the Nevisense system in cutaneous melanoma detection: an international, multicentre, prospective and blinded clinical trial on efficacy and safety. The British journal of dermatology, 171(5), 1099-107.

Even though progress has been made, the detection of melanoma still poses a challenge. In light of this situation, the Nevisense electrical impedance spectroscopy (EIS) system (SciBase AB, Stockholm, Sweden) was designed and shown to have the potential to be used as an adjunct diagnostic tool for melanoma detection.

Garrett, G. L., Blanc, P. D., Boscardin, J., Lloyd, A. A., Ahmed, R. L., Anthony, T., Bibee, K., Breithaupt, A., Cannon, J., Chen, A., Cheng, J. Y., Chiesa-Fuxench, Z., Colegio, O. R., Curiel-Lewandrowski, C., Del Guzzo, C. A., Disse, M., Dowd, M., Eilers, R., Ortiz, A. E., , Morris, C., et al. (2017). Incidence of and Risk Factors for Skin Cancer in Organ Transplant Recipients in the United States. JAMA dermatology.

Skin cancer is the most common malignancy occurring after organ transplantation. Although previous research has reported an increased risk of skin cancer in solid organ transplant recipients (OTRs), no study has estimated the posttransplant population-based incidence in the United States.

Hu, S., Kim, C. C., Jessup, C., Phung, T. L., & Curiel, C. N. (2009). Primary cutaneous melanomas presenting as inflamed pigmented lesions during adjuvant interferon treatment: an important diagnostic clue for clinicians. Arch Dermatol, 145(5), 565-8.
Curiel-Lewandrowski, C. N., Krase, I., & Cavanaugh, K. (2016). Rupoid Syphilis. J am Acad Dermatol.
Curiel-Lewandrowski, C., Swetter, S. M., Einspahr, J. G., Hsu, C., Nagle, R., Sagerman, P., Tangrea, J., Parnes, H., Alberts, D. S., & Chow, H. (2012). Randomized, double-blind, placebo-controlled trial of sulindac in individuals at risk for melanoma: evaluation of potential chemopreventive activity. Cancer, 118(23), 5848-56.

Reduced melanoma risk has been reported with regular use of nonsteroidal anti-inflammatory drugs (NSAIDs). However, the ability of NSAIDs to reach melanocytes in vivo and modulate key biomarkers in preneoplastic lesions such as atypical nevi has not been evaluated.